
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is positioned for growth in the pharmaco-epigenetics space due to ongoing collaborations and partnerships, which could enhance revenue and facilitate the adoption of its biomarker technology. The validation of the Nu.Q Lung Cancer Test is expected to de-risk the technology and attract strategic partnerships, further solidifying its appeal within the diagnostics market. Additionally, the introduction of an automated system in veterinary diagnostics and the successful adoption of Nu.Q Discover biomarkers in over 1,000 veterinary hospitals in Japan indicate a strong market interest and a potential increase in revenue capacity for the company.
Bears say
VolitionRX Ltd's focus on developing blood tests using its Nucleosomics platform faces financial challenges, particularly due to the ongoing issues related to high false-positive rates in lung cancer screenings, which may undermine the reliability of its diagnostic tests. The company's financial performance is potentially jeopardized as the need for further validation studies may delay commercialization and increase costs, impacting revenue generation. Additionally, the reliance on clinical studies to validate its products can result in significant uncertainty regarding future cash flows and overall market acceptance, thus placing strain on investor confidence and stock performance.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares